| |
Type of Inoculum
|
αS Pathology
|
Microgliosis
|
Astrogliosis
|
|---|
|
nTg
|
PBS
|
–
|
+/−
|
+/−
|
|
nTg
|
Control Lysate
|
–
|
+/−
|
+/−
|
|
nTg
|
MSA Lysate
|
–
|
+/−
|
+/−
|
|
M20+/−
|
PBS
|
–
|
+/−
|
+/−
|
|
M20+/−
|
Control Lysate
|
–
|
+/−
|
+/−
|
|
M20+/−
|
MSA Lysate
|
–
|
+/−
|
+/−
|
|
M83+/−
|
PBS
|
–
|
+/−
|
+/−
|
|
M83+/−
|
Control Lysate
|
–
|
+/−
|
+/−
|
|
M83+/−
|
MSA Lysate
|
+++
|
++
|
+++
|
|
M83+/−
|
WT αS Fibrils
|
+
|
+
|
++
|
|
M83+/−
|
A53T αS Fibrils
|
++
|
+
|
++
|
- For each mouse line, qualitative neuropathological grading of pathological inclusion burden and immunological response induced by each inoculum was graded on the following scale: (+/−) rare, (+) mild, (++) moderate, and (+++) severe. This grading for M83+/− injected with MSA lysates only include the mice that developed αS inclusion pathology
